Title: News Voids: How to Keep Investors and Strategics Engaged During Data Deserts
Date:
Time:
Interested parties may register for the event here.
H.C. Wainwright Bioconnect Conference
Presentation Date:
Presentation Time:
Please contact your representative at H.C. Wainwright to schedule a virtual one-on-one meeting.
Allogeneic Cell Therapies Summit Europe (Virtual),
Professor
Title: Academic to Commercial Development of an Off-the-Shelf Allogeneic ATMP: Three Clinical Trial Case Studies
Date:
Time:
Interested parties may register for the Summit here.
About
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the
INmune Bio Contact:
DMoss@INmuneBio.com
Investor Contact:
(646) 627-8390
chuck@lifesciadvisors.com
Source:
2022 GlobeNewswire, Inc., source